The discovery of this tumor-protecting biochemical pathway advanced our understanding of pharmacological approaches to block the early stages (hypoxia/HIF1A) and late stages (adenosine/A2AR/cAMP) of this signaling axis. Here, HIF1A is linked to neoplasm.